Case Study 1 in brief: A 55-year-old male diagnosed with advanced bile duct cancer underwent conventional chemotherapy with limited success. After introducing GcMAF into his treatment regimen, his immune markers showed significant improvement. Over six months, imaging studies revealed a drastic reduction in tumor size, and the patient reported better energy levels and overall quality of life.  

 Case Study 2 in brief:  A 62-year-old female with metastatic bile duct cancer was treated with GcMAF in combination with standard chemotherapy. Her treatment response was monitored through regular blood tests and imaging. The patient experienced a notable decrease in tumor markers and stabilization of metastatic sites. Additionally, she reported fewer side effects from chemotherapy, suggesting a synergistic effect of GcMAF. 

Please understand that GcMAF was not used alone. The hospital used their own I.V protocol in which they adapt on a case-by-case basis.  This patient was also helped by a team of 50 doctors working together. Every decision is well thought out. These case studies highlight the potential benefits of GcMAF in enhancing the immune response and improving patient outcomes in bile duct cancer.